Andrew D. Davidson

Pfizer (United States) — United States

Medicine · Health Sciences

52h-index9.9kcitations208works5.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

SARS-CoV-2 and COVID-19 Research(81), Mosquito-borne diseases and control(44), Viral Infections and Vectors(28), COVID-19 Clinical Research Studies(25), interferon and immune responses(23)

Publications206 total

pH-induced structural changes in SARS-CoV-2 spike variants
2025Open Access
Mosquito NF-κB-mediated innate immunity exerts arbovirus-specific antiviral effects at multiple stages of the viral life cycle
2025Open Access
Green and white analytical chemistry: Advances, comparisons, future perspectives, and a proposal for green financing model for analytical chemistry
Journal of Pharmaceutical Sciences·2025· 3 cited
Early NK-cell and T-cell dysfunction marks progression to severe dengue in patients with obesity and healthy weight
Nature Communications·2025· 5 citedOpen Access
Hybrid B- and T-Cell Immunity Associates With Protection Against Breakthrough Infection After Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination in Avon Longitudinal Study of Parents and Children (ALSPAC) Participants
The Journal of Infectious Diseases·2025· 2 citedOpen Access
886 A feasibility trial of delayed resection for brain metastases following pre-operative stereotactic radiosurgery
Radiotherapy and Oncology·2025
A Novel Toolkit of SARS-CoV-2 Sub-Genomic Replicons for Efficient Antiviral Screening
Viruses·2025· 1 citedOpen Access
Allosteric modulation by the fatty acid site in the glycosylated SARS-CoV-2 spike
eLife·2025· 2 citedOpen Access
A sensitive multiplex RT-qPCR assay to detect SARS-CoV-2 in respiratory samples
2025
Author response: Allosteric modulation by the fatty acid site in the glycosylated SARS-CoV-2 spike
2025Open Access
Examining the feasibility of replacing ORF3a with fluorescent genes to construct SARS-CoV-2 reporter viruses
Journal of General Virology·2025· 1 citedOpen Access
SARS-CoV-2 memory response in non-hospitalised cases: immunology in the context of a population-based cohort study
Wellcome Open Research·2024· 1 citedOpen Access
Allosteric modulation by the fatty acid site in the glycosylated SARS-CoV-2 spike
2024· 1 citedOpen Access
Hybrid adaptive immunity to SARS-CoV-2 protects against breakthrough infection after COVID-19 vaccination in ALSPAC participants
2024Open Access
Sequential Infection with Influenza A Virus Followed by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Leads to More Severe Disease and Encephalitis in a Mouse Model of COVID-19
Viruses·2024· 18 citedOpen Access
Ambient carbon dioxide concentration correlates with SARS-CoV-2 aerostability and infection risk
Nature Communications·2024· 52 citedOpen Access
The α-dystroglycan N-terminus is a broad-spectrum antiviral agent against SARS-CoV-2 and enveloped viruses
Antiviral Research·2024· 3 citedOpen Access
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) culture and sample preparation for correlative light electron microscopy
Methods in cell biology·2024· 1 cited
Broad-spectrum antiviral activity of two structurally analogous CYP3A inhibitors against pathogenic human coronaviruses in vitro
Antiviral Research·2023· 4 citedOpen Access
The α-dystroglycan N-terminus is a broad-spectrum antiviral agent against SARS-CoV-2 and enveloped viruses
2023Open Access
page 1 of 11Next →

Frequent Co-authors

David A. Matthews(13), Maia Kavanagh Williamson(9), Kate J. Heesom(7), Deborah K. Shoemark(6), Julian A. Hiscox(6), P.J. Wright(6), Michael Jacobs(5), Miles W. Carroll(4), Richard B. Sessions(3), Philip A. Lewis(3), Stuart G. Siddell(3), R.E. Butcher(3), Subhash G. Vasudevan(3), Pei‐Yong Shi(3), Amjad Yousuf(3), Siew Pheng Lim(3), James L. Daly(2), Boris Simonetti(2), Katja Klein(2), Carlos Antón-Plágaro(2)